Scripps Research Institute and OPKO Health Announce Global License Agreement for a Novel Neuroprotective Compound

OPKO Health has licensed technology developed by researchers from The Scripps Research Institute studying the jun-N-terminal kinase (JNK) pathway. The company plans to commercially develop the small molecule JNK inhibitor SR3306 as a neuroprotective compound for the treatment of neurodegenerative diseases.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail